Long COVID-19 and the Heart

Smidt Heart Institute Experts Highlight What They Now Know About the Impact of the Virus on the Heart

Translate to Spanish or other 102 languages!

Smidt Heart Institute physicians have found that COVID-19's effects on the heart are treatable and reversible. Illustration by Getty Images / Via Cedars Sinai.
Smidt Heart Institute physicians have found that COVID-19’s effects on the heart are treatable and reversible. Illustration by Getty Images / Via Cedars Sinai.

Mega Doctor News

- Advertisement -

CEDARS-SINAI – After treating COVID-19 survivors for nearly two years, cardiologists in the Smidt Heart Institute at Cedars-Sinai highlight what they have learned about the impact of the virus on the heart—and how to most effectively treat patients who are recovering from these varying conditions.    

“Since our clinic founding in late 2020, we have treated more than 100 patients with specific heart-related concerns due to COVID-19,” said Siddharth Singh, MD, director of the Post COVID-19 Cardiology Clinic in the Smidt Heart Institute. This first-of-its-kind program was created uniquely for COVID-19 survivors, with an added goal of aiding ongoing research.

The take-home message, which Singh hopes will bring a sense of comfort to virus survivors, is that long-lasting damage to the heart due to COVID-19 is rare and treatable.

- Advertisement -

“We are encouraged that patients are recovering from long COVID-19 and getting back to their everyday activities and lives,” said Singh, also an assistant professor of Cardiology at Cedars-Sinai.

Who is At Risk? 

As COVID-19 continues to spread around the world, researchers have learned that the cardiovascular system can be affected in patients who experienced minor or no symptoms as well as patients who were severely ill with the virus.

“Patients with preexisting heart and vascular issues may be at an increased risk for developing long-lasting complications from COVID-19,” said Eduardo Marbán, MD, PhD, executive director of the Smidt Heart Institute and the Mark S. Siegel Family Foundation Distinguished Professor. “Given the ubiquity of COVID-19, recognition of potential long-term health issues is important as we learn more about the virus and its aftereffects.”

- Advertisement -

The major cardiovascular issues affecting COVID-19 survivors include problems with fast heart rate and lightheadedness, especially when upright—also referred to as postural orthostatic tachycardia syndrome (POTS), or dysautonomia—chest pain linked to inflammation in the lining of the sac that surrounds the heart, difficulty exercising due to shortness of breath, and heart arrhythmias.

“For these conditions, we have utilized well-studied cardiovascular therapies to treat patients,” said Singh.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Robotic Surgery Program Expanded at STHS McAllen

From smaller incisions and less pain to shorter hospital stays and faster recovery times, robotic-assisted surgery is changing the way patients experience surgical care.

Texas Oncology to Host Breast Cancer Awareness Symposium in McAllen. FULL TO CAPACITY. NO MORE ROOM.

The Breast Cancer Awareness Symposium 2026 is an educational and networking event hosted by Texas Oncology and sponsored by Caris Life Sciences, bringing together oncology specialists, surgeons, advanced practice providers, and community healthcare professionals to discuss the latest advances in breast cancer prevention, diagnosis, treatment, survivorship, and reconstruction. The symposium's theme, "Breast Cancer 2026: Early Detection, Modern Care, and Survivorship Through Community Partnership," highlights the importance of multidisciplinary collaboration and patient-centered care

Highway Crash Leads to Unexpected STC Connection

What began as a flat tire on the side of a highway turned into a frightening collision and an unexpected encounter for South Texas College faculty member Jesus Amaya, when the paramedic who responded to the scene turned out to be one of STC’s graduates.

FDA Approves Immunotherapy Regimen Studied by Mayo Clinic for Stage 3 Colon Cancer

The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair, or dMMR.
- Advertisement -